<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218828</url>
  </required_header>
  <id_info>
    <org_study_id>KP-RCCL-5718</org_study_id>
    <nct_id>NCT01218828</nct_id>
  </id_info>
  <brief_title>Prevention of Contrast Renal Injury With Different Hydration Strategies</brief_title>
  <acronym>POSEIDON</acronym>
  <official_title>Hydration With Different Sodium Chloride Protocols for the Prevention of Contrast Medium-induced Nephropathy in Patients Undergoing Coronary Angiography: a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using a randomized controlled trial design, two hydration protocols for the prevention of
      contrast medium-induced nephropathy will be tested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population will be recruited from subjects undergoing cardiac catheterization.

      Subjects will be randomized to one of two hydration protocols:

        1. normal saline at 3 mL/kg for one hour prior to contrast exposure and 1.5 mL/kg/hr during
           and for four hours post procedure.

        2. normal saline at 3 mL/kg for one hour prior to contrast exposure and then the fluid rate
           would be adjusted according to the left ventricular end diastolic pressure (LVEDP). The
           fluid rate based upon the LVEDP measurement is maintained during the procedure and for
           four hours post procedure. The LVEDP hydration strategy follows: (2A) &lt; 13 mmHg, 5
           mL/kg/hr during and for four hours post procedure. (2B) 13-18 mmHg, 3 mL/kg during and
           for four hours post procedure. (2C) &gt; 18 mmHg, 1.5 mL/kg during and four hours post
           procedure.

      Renal function assessment will be made using standard laboratory measures post procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast induced nephropathy</measure>
    <time_frame>Within four days of contrast exposure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy, myocardial infarction, all-cause mortality</measure>
    <time_frame>30 days and long-term</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">396</enrollment>
  <condition>Contrast Medium-induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydration with 0.9% saline per a standard protocol (control group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LVEDP-based hydration strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LVEDP guided hydration with 0.9% saline (treatment group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LVEDP -Based hydration strategy</intervention_name>
    <arm_group_label>LVEDP-based hydration strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard hydration</intervention_name>
    <arm_group_label>Standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  estimated GFR less than or equal to 60 mL/min/1.73 m^2

          -  age greater than 18 years

          -  at least one of the following: diabetes mellitus, history of congestive heart failure,
             hypertension, or age greater than 75 years.

        Exclusion Criteria:

          -  patients unable to give consent

          -  undergoing emergency cardiac catheterization

          -  on renal replacement therapy

          -  exposure to contrast media within the prior two days

          -  pulmonary edema or active congestive heart failure

          -  kidney transplant status

          -  severe valvular abnormalities

          -  change in serum creatinine greater than 15% over the prior two days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Somjot S Brar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contrast</keyword>
  <keyword>nephropathy</keyword>
  <keyword>cardiac catheterization</keyword>
  <keyword>angiography</keyword>
  <keyword>percutaneous coronary intervention is</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

